NASDAQ: BIOABioage Labs Inc Stock
$3.87+0.12 (+3.2%)
Updated Apr 17, 2025
BIOA Price
$3.87
Fair Value Price
N/A
Market Cap
$138.74M
52 Week Low
$2.88
52 Week High
$26.62
P/E
-0.58x
P/B
0.43x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$71.11M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$52M
Beta
0.82
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BIOA Overview
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BIOA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
BIOA
Ranked#51 of 54
Ranked#51 of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.36 | A | |
| $24.65 | A | |
| $13.76 | A |
Be the first to know about important BIOA news, forecast changes, insider trades & much more!
BIOA News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BIOA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIOA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BIOA is good value based on its book value relative to its share price (0.43x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.99x)
P/B vs Industry Valuation
BIOA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BIOA due diligence checks available for Premium users.
Valuation
BIOA fair value
Fair Value of BIOA stock based on Discounted Cash Flow (DCF)
Price
$3.87
Fair Value
-$4.23
Undervalued by
191.40%
BIOA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BIOA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.58x
Industry
20.48x
Market
27.98x
BIOA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.43x
Industry
1.99x
BIOA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BIOA's financial health
Profit margin
Revenue
$0.0
Net Income
-$21.1M
Profit Margin
0%
BIOA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$358.2M
Liabilities
$35.1M
Debt to equity
0.11
BIOA's short-term assets ($357.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIOA's short-term assets ($357.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIOA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.1M
Investing
-$26.0k
Financing
$24.9M
BIOA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BIOA vs Pharmaceutical Stocks
Bioage Labs Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.